CDKN2A and endometrial cancer: Endometrioid endometrial cancers, which made up of 99% of endometrial cancer cases included on the TMA, had an expression profile intermediate to that of non-serous and serous ovarian cancers, with high expression of p16 and low expression of the other markers.